#stem cell assays market

[healthcare-domain]

According to the new market research report “Stem Cell Assays Market by Type (Viability, Proliferation, Differentiation, Apoptosis), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instrument), Application (Regenerative Medicine, Clinical Research), End User - Global Forecast to 2027”, published by MarketsandMarkets™, the global market is projected to reach USD 4.5 billion by 2027 from USD 1.9 billion in 2022, at a CAGR of 17.7 % during the forecast period of 2022 to 2027.

[global-research-report]

The Evolving Flow Cytometry Market: Key Trends and Opportunities in 2025

The global flow cytometry market size is expected to reach USD 7.01 billion by 2030, registering a CAGR of 6.96% over the forecast period, according to a new report by Grand View Research, Inc. Technological advancements in the technique are introducing new and improved analytical tools, which include the development of microfluidic flow cytometry for Point-of-Care (PoC) testing. Furthermore, the rising prevalence of cancer, immunodeficiency disorders, and infectious diseases is driving the industry. In addition, increasing R&D investments in biopharmaceutical, life science, and biotechnology research activities have led to high demand for flow cytometry instruments. In recent years, a key focus has been on the development of portable microfluidic flow cytometry devices for PoC testing.

Microfluidics and flow cytometry together make a useful tool to measure multiple characteristics of biological samples. For instance, the easy availability of several microfluidics and miniaturized detectors have enabled the creation of microchip-based cytometers, such as optofluidic cytometer, imaging cytometer, and impedance cytometer. The development of microfluidic flow cytometry devices, which are cost-effective, portable, and compact, is beneficial. They are affordable in developing economies, such as Asia & Africa, and are enabling rapid growth in PoC testing applications. Furthermore, improvements in fluorescent dyes and the increasing utility of benchtop cytometers for academic research settings are expected to drive the industry.

Developments in multicolor flow cytometry are accelerating the adoption of the technique in novel drug development activities. For instance, in January 2020, DxFLEX, CE-IVD, a 13-colour clinical flow cytometry system was launched by Beckman Coulter Life Sciences in Europe. Similarly, easy cellular analysis by simultaneous evaluation of several parameters allows extensive use of such devices for contract research purposes. The COVID-19 pandemic also spurred innovations in the technique, as evidenced by the launch of new products in this domain. For instance, in July 2021, Metropolis Healthcare Ltd. launched CoviRisk-TBNK, a simple blood test to detect the risk status of a COVID-19 hospitalized patient.

It helps analyze patients’ need for ICU facilities or ventilation and aids in the reduction of stress on healthcare resources. The test is a flow cytometry-based lymphocyte subset assay and is IVD-approved. Such innovations are anticipated to fuel industry growth in the near future. Moreover, flow cytometry is a significant tool in listing and characterizing immune cells, and is also helpful in recognizing and validating underlying genetic defects. The technique is also used to observe and monitor the immune response of patients after stem cell transplantation, and hence, organ transplantation plays an important role in boosting industry growth. According to the WHO, around 50,000 stem cell transplantations are performed globally every year, and this number is expected to grow in the near future, broadening the scope of applications for the technique.

On the other hand, instruments are highly expensive, and hence, buyers in several developing countries may not be able to afford technologically advanced flow cytometry equipment. These instruments may cost over USD 100,000 and pose significant budgetary constraints for small- & mid-sized hospitals and clinical laboratories. However, some manufacturers, such as Sony, are trying to launch newer instruments using software to automate a number of processes. Such developments would not only improve the usability of the technique but also help bring down the average instrumentation cost-under USD 100,000-in the near future.

Flow Cytometry Market Report Highlights

The instrument product segment held the largest share in 2023 due to technical advancements, as well as increased prevalence of chronic conditions

The cell-based flow cytometry technology dominated the industry in 2023 due to the high demand for early diagnosis and rising awareness about the associated benefits of cell-based assays

By application, the clinical segment accounted for the largest revenue share in 2023 owing to increased activities pertaining to infectious diseases, such as influenza, HIV, and COVID-19, among others

The academic institutes end-user segment led the market in 2023 owing to increased R&D activities by academic institutes & research centers

North America was the leading region in 2023 due to the high implementation of scientifically advanced flow cytometry solutions, high healthcare expenditure, and well-established healthcare infrastructure in the region

Asia Pacific is expected to register the fastest CAGR from 2022 to 2030 owing to the extensive growth in the pharmaceutical and biotechnology industries in emerging economies, such as China and India

Flow Cytometry Market Segmentation

Grand View Research has segmented the global flow cytometry market report based on product, technology, application, end-use, and region:

Flow Cytometry Technology Outlook (Revenue, USD Million, 2018 - 2030)

Instruments

Cell Analyzers

Cell Sorters

Reagents & Consumables

Software

Accessories

Services

Flow Cytometry Technology Outlook (Revenue, USD Million, 2018 - 2030)

Cell-based

Bead-based

Flow Cytometry Application Type Outlook (Revenue, USD Million, 2018 - 2030)

Research

PharmaceuticalApoptosis

Drug Discovery

Stem Cell

In Vitro Toxicity

Cell Sorting

Cell Cycle Analysis

Immunology

Cell Viability

Others

Industrial

Clinical

Cancer

Organ Transplantation

Immunodeficiency

Hematology

Autoimmune Disorders

Flow Cytometry End-use Outlook (Revenue, USD Million, 2018 - 2030)

Commercial Organizations

Biotechnology Companies

Pharmaceutical Companies

CROs

Hospitals

Academic Institutes

Clinical Testing Labs

Flow Cytometry Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Europe

UK

Germany

France

Italy 

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

Singapore

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

List of Key Players

Danaher

BD

Sysmex Corporation

Agilent Technologies, Inc.

Apogee Flow Systems Ltd.

Bio-Rad Laboratories, Inc.

Thermo Fisher Scientific, Inc.

Stratedigm, Inc.

Miltenyi Biotec

Cytek Biosciences

Sony Group Corporation (Sony Biotechnology Inc.)

Order a free sample PDF of the Flow Cytometry Market Intelligence Study, published by Grand View Research.

[willyskristina]

Apoptosis Assays Market

Apoptosis Assays Market Size, Share, Trends: Thermo Fisher Scientific Inc. Leads

Shift Towards Multiplexed and High-Throughput Apoptosis Assays for Comprehensive Cell Death Analysis

Market Overview:

The global apoptosis assays market is expected to develop at a CAGR of 8.2% between 2024 and 2031. North America now dominates the market, accounting for over 35% of total worldwide share. Key metrics include the expanding prevalence of chronic diseases, increased R&D investments in drug discovery, and the growing use of high-throughput screening techniques.

The Apoptosis Assays Market is expanding rapidly, owing to a growing emphasis on personalised treatment and increased need for targeted cancer medicines. The market is seeing an increase in technological improvements, particularly in flow cytometry and high-content screening technologies, which improve the accuracy and efficiency of apoptosis detection. Furthermore, the rising uses of apoptosis tests in stem cell research and regenerative medicine are creating new opportunities for market growth.

DOWNLOAD FREE SAMPLE

Market Trends:

The Apoptosis Assays Market is seeing a substantial shift towards multiplexed and high-throughput assays, driven by the need for more thorough and efficient cell death studies. This shift allows researchers to assess several apoptotic characteristics, such as caspase activation, mitochondrial membrane potential, and DNA fragmentation, in a single experiment. The use of sophisticated assays is especially prevalent in drug discovery and development processes, where rapid and reliable screening of vast chemical libraries is essential.

For example, a recent study in the Journal of Biomolecular Screening found that using multiplexed apoptosis assays in high-throughput screening campaigns resulted in a 40% reduction in false positives when compared to standard single-parameter assays. This increase in accuracy and efficiency is fuelling demand for multiplexed apoptosis assay kits and reagents. Furthermore, the use of artificial intelligence and machine learning algorithms in data analysis improves the interpretation of complicated apoptotic information, allowing researchers to detect subtle trends and prospective treatment candidates more efficiently.

The move towards multiplexed and high-throughput apoptosis testing is encouraging collaborations between academic institutions and pharmaceutical businesses. These collaborations aim to create new test formats and broaden the usage of apoptosis assays in fields like immunology and neurodegenerative disease research. As a result, the market is seeing a boom in product innovation, with several major manufacturers releasing next-generation apoptosis detection platforms with higher sensitivity, repeatability, and throughput.

Market Segmentation:

Caspase assays dominate the Apoptosis Assays Market, accounting for approximately 40% of the market share in 2023. Caspase assays have emerged as the leading sector in the Apoptosis Assays Market, owing to their high specificity and sensitivity in detecting important hallmarks of programmed cell death. These assays are essential for a variety of applications, including drug development, toxicity assessment, and fundamental cell biology research. Caspase assays dominate because of their versatility in detecting both early and late phases of apoptosis, as well as their compatibility with a variety of detection platforms.

Recent advances in caspase assay technologies have strengthened their commercial position. For example, the advent of real-time caspase assays has allowed researchers to track apoptosis dynamics in live cells, providing important insights into the temporal features of cell death. A study published in Nature Methods found that real-time caspase tests might identify apoptosis initiation up to 4 hours sooner than standard end-point assays, considerably increasing the sensitivity of drug screening programs.

The pharmaceutical sector has been a major driver of the caspase assays segment, with a growing number of drug discovery programs including these assays into their screening processes. Over 60% of oncology drug discovery projects currently use caspase-based assays in their early-stage chemical screening processes, according to Biotechnology Innovation Organisation (BIO) research. The importance of apoptosis in cancer progression, as well as the possibility of caspase-targeted medicines in cancer treatment, are driving this widespread acceptance. Furthermore, the combination of caspase assays and high-content imaging systems has created new opportunities for multiplexed investigation of apoptotic processes. Leading life science businesses reported a 30% year-over-year increase in multiplexed caspase assay kit sales, indicating a growing demand for complete apoptosis profiling in university and industrial research contexts. This tendency is projected to continue driving the caspase assays segment further in the coming years.

Market Key Players:

Thermo Fisher Scientific Inc.

Merck KGaA

Bio-Rad Laboratories, Inc.

Becton, Dickinson and Company

Abcam plc

Promega Corporation

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[colinwilson11]

Cell Cytometry Market Poised To Expand Rapidly Due To Growing Investment In R&D Activities

The cell cytometry market allows observation, analysis, separation and purification of cells using multiple parameters of light scattering, fluorescent dyes and other optical instrumentation. Cell cytometry helps understanding cell populations, cell characteristics, cell structures and analyzing cellular functions at single-cell level. It aids in research associated with cancer, AIDS, and other diseases and has applications in areas of immunology, hemopathology and stem cell research.

The cell cytometer market includes flow cytometers, high-content screening systems, and other equipment, reagents, and software. Flow cytometers are most widely used cell analyzers that allow multiparametric analysis of physical and biochemical characteristics of single cells suspended in fluid medium. The increasing prevalence of chronic and infectious diseases is driving growth in cell-based research activities and clinical applications of cell cytometry technologies.

The Cell Cytometry Market is estimated to be valued at US$ 1.5 Bn in 2024 and is expected to exhibit a CAGR of 9.9% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the cell cytometry market are Agilent, Beckton Dickinson, Beckman Coulter Life Sciences, Bio-Rad, and ThermoFisher Scientific. Key players are focusing on developing advanced flow cytometer systems and reagents with increased sensitivity, higher throughput, and expanded application areas. For instance, in 2022 Agilent launched NovoCyte Penta which provides 5 lasers for multicolor assays.

The cell cytometry market is witnessing high growth due to increasing demand for disease diagnostics and therapeutics related to immunology, cancer, and stem cell research. Growing biopharmaceutical industry investments in cell-based research and biomarker discovery arefueling adoption of cell analysis platforms. The advancements in single-cell analysis technologies are augmenting market opportunities in translational research, personalized medicine and drug discovery.

Technological advancements are playing a major role in market growth. Integration of informatics and artificial intelligence solutions in cell analysis platforms is helping to improve data analysis and accelerate scientific discoveries. Adoption of microfluidic chips and microfluidics technologies is supporting development of compact portable instruments with high sensitivity for point-of-care applications. Automation of workflow processes using robotics is enhancing throughput and reproducibility.

Market Trends

Two major trends are driving innovation in the cell cytometry market. First, the incorporation of artificial intelligence and machine learning algorithms in cell analysis software is helping in automated segmentation, gating, classification and biomarker identification from large and complex flow and imaging cytometry data sets. This aids high content analysis and phenotypic screening applications. Second, the development of cell isolation platforms integrated with downstream multi-omics capabilities for single-cell proteomics, transcriptomics and genome analysis is supporting personalized medicine initiatives like cancer immunotherapy development.

Market Opportunities

Emerging economies in Asia Pacific and Latin America represent major growth opportunities for cell analysis product manufacturers due to increasing pharmaceutical outsourcing, rising healthcare investments and establishment of new life sciences research institutes. Second, the expansion of stem cell based research and growing adoption of cell therapy products will augment demand for cell sorting, cell characterization and potency analysis capabilities. This offers novel opportunities for companies to introduce specialized cell analysis platforms.

The covid-19 pandemic has negatively impacted the growth of the cell cytometry market in the short run. During pre-covid times, the market was growing at a steady pace due to increased investments in r&d for drug development and discovery. However, nationwide lockdowns imposed travel restrictions and disrupted the global supply chains. This affected the procurement of key instruments, reagents and consumables necessary for cell cytometry procedures in research laboratories and healthcare facilities.

With lockdowns easing in late 2020, the market is recovering slowly as r&d activities are resuming. However, budgetary reallocations to test,treat and vaccinate large populations have reduced funding available for non-covid research. This is hampering the market growth. The key players are struggling to enhance production capacities due to labour shortages and raw material delays. They are now focusing on developing reagents and assays suited for covid-19 research to leverage new opportunities.

Going forward, collaborations between industry and academia will be important to expand the applications of cell cytometry in vaccine development,immune response monitoring and target identification for covid therapeutics. Government support through public-private partnerships can help bolster healthcare infrastructure and rebuild market confidence. Automated high throughput platforms allowing for fast,simultaneous processing of samples can aid in pandemic preparedness. Finally, virtual demonstrations and online training programmes can compensate for restrictions on field interactions until the pandemic subsides fully.

North America is currently the largest market for cell cytometry accounting for over 40% of the global revenues, followed by Europe and Asia Pacific. This is due to extensive r&d spending and presence of leading lifesciences companies and research institutes in USA and Western Europe which are early adopters of advanced cell analysis technologies. The Asia Pacific region excluding Japan presents the strongest growth prospects during the forecast period, propelled by increasing healthcare investments,expanding biotech industries and rising affluence in populous nations like China and India.

Over the next decade, cell cytometry markets in countries like Brazil, South Korea and Saudi Arabia are also expected to grow substantially under the influence of supportive government policies and initiatives driving innovation. The universal need to better understand disease mechanisms, accelerate drug development and improve clinical outcomes will continue driving the long term demand for cell analysis technologies regardless of ongoing economic or health sector challenges.

Get more insights on this topic: https://www.ukwebwire.com/cell-cytometry-market-is-estimated-to-witness-high-growth-owing-to-advancements-in-multi-color-flow-cytometry/

About Author:

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn - https://www.linkedin.com/in/priya-pandey-8417a8173/)

What Are The Key Data Covered In This Cell Cytometry Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Cell Cytometry Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Cell Cytometry Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Cell Cytometry Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Cell Cytometry Market vendors

FAQ’s

Q.1 What are the main factors influencing the Cell Cytometry Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Cell Cytometry Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Cell Cytometry Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[market-insider]

Exploring the 3D Cell Culture Market: From Research to Real-World Impact

The global 3D cell culture market size is anticipated to reach USD 3.21 billion by 2030 and is anticipated to expand at a CAGR of 11.22% during 2024 to 2030, according to a new report by Grand View Research, Inc. The market is driven by technological advancements in in-vitro testing models, a rising focus on personalized medicine, and supportive government legislation for R&D. Moreover, the increasing prevalence of chronic disorders, and the growing significance of cell therapies in their treatment have created momentum for industry expansion.

Tissue engineering has made significant developments in creating 3D culture models that mimic the in-vivo culture media more precisely than the conventional 2D cell cultures. This resulted in increased utilization of 3D cell culture systems for toxicity testing, drug discovery, and regenerative medicine development. Also, recent product launches from industry players have supported market growth to a significant extent. For instance, in June 2023, Pixelgen Technologies launched its first molecular pixelation kit for 3D spatial study of proteins present on cell surface.

In addition, the development of advanced technologies like microfluidics, bioprinting, and high-content screening systems, has leveraged the capabilities of these models. These technologies allow excellent control over culture conditions, cell organization, and the capability to perform high-efficiency screening, thereby fueling the utilization of 3D culture systems. Moreover, increased collaboration between market players to utilize bioprinting and microfluidics techniques in developing culture models has propelled market growth. For instance, in June 2023, AIM Biotech and MatTek partnered together to offer innovative idenTX and organiX microfluidic 3D tissue culture platforms along with complete drug discovery research services in specific areas of neurobiology, immune-oncology, and vascular biology.

3D cultures can closely replicate the typical microarchitecture and morphology of organs and hence are continuously developed for studies that require in vivo models to analyze the effect of a drug over body tissues and organs. This factor, coupled with the availability of several choices in terms of the material and structure of the scaffold for a variety of in-vitro applications, is anticipated to boost revenue generation for scaffolds. Recent research has explored the use of a broad range of scaffolds, such as graphene scaffolds, nanofibers, natural marine collagen, freeze-casting, and others. In addition, emerging applications of techniques such as lab-on-a-chip in several assay types, including proliferation, stimulation, viability, transport, high content screening, patch clamping, and metabolic activity are anticipated to lead to an increase in demand for advanced and efficient solutions.

However, the lack of consistency in 3D cell model products is one of the major drawbacks that is expected to hinder the growth of the market. Moreover, various factors such as variability in cell culture, standardized challenges, scale & manufacturing issues, and quality control issues might hamper the market growth.

For More Details or Sample Copy please visit link @: 3D Cell Culture Market Report

3D Cell Culture Market Report Highlights

The scaffold-based technology segment dominated the market in 2023 with a revenue share of 48.94% and is attributed to the increasing application of scaffold-based cultures in tissue engineering and regenerative medicine applications

Stem cell research & tissue engineering held the largest share in 2023, whereas the cancer institute segment is expected to witness the fastest growth owing to the rising prevalence of cancer, and the benefits offered by 3D cell cultures in cancer research

In the end-use segment, biotechnology and pharmaceutical companies dominated the market with a revenue share in 2023. The higher revenue growth is attributed to the continuous growth and commercial success of biopharmaceuticals coupled with the expanding portfolio of the major pharmaceutical companies

North America region dominated the global market in 2023 with a revenue share of 38.97%, owing to the presence of advanced healthcare infrastructure, developed economies, the presence of key players, and various strategic initiatives undertaken by them

Gain deeper insights on the market and receive your free copy with TOC now @: 3D Cell Culture Market Report

We have segmented the global 3D cell culture market based on technology, application, end-use, and region.

[industrynewsupdates]

Oligonucleotide Synthesis Market Analysis And Segment Forecast 2024-2030

The global oligonucleotide synthesis market size was estimated at USD 3.68 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.21% from 2024 to 2030. 

The decreasing prices of sequencing have led to increasing demand for custom-made nucleotides for applications across genetic testing, research, forensics applications, and drug development. This has further boosted the demand for oligonucleotide synthesis. The COVID-19 pandemic has affected every market globally and there has been a surge in the demand for efficient treatment against COVID-19.

Gather more insights about the market drivers, restrains and growth of the Oligonucleotide Synthesis Market

Oligonucleotide therapeutics hold immense potential for treating chronic conditions such as cardiovascular diseases, cancers, and retinal disorders. Emerging new applications of oligo sequences in multiple fields of biotechnology are expected to increase market growth. Demand for molecular diagnostics in precision care is an important emerging application field for oligonucleotide synthesis.

The introduction of advanced techniques such as CRISPR and high-throughput sequencing for gene expression analysis has simplified the genetic screening and modification of genomes. Such innovations are observed to influence the demand for oligonucleotide synthesis. Manufacturers invest in technology development to enable the production of long Oligonucleotides with higher precision and better yield to cater to the growing need for custom oligos.

The availability of a regulatory environment that supports the progress of genomics is the key factor contributing to the market growth. Changes in the regulatory policies to provide a well-framed environment for advanced biological research and application in human use are expected to influence demand for oligonucleotide synthesis significantly. Stem cells, regenerative medicine, genetic engineering, and synthetic biology are the prominent fields identified with high potential in healthcare. For instance, the International Society for Stem Cell Research (ISSCR) ethics and public policy committee aims to recognize and resolve issues by conducting open discussions. The committee includes experts in ethics, law, and social policy worldwide.

Oligonucleotide Synthesis Market Segmentation

Grand View Research has segmented the global oligonucleotide synthesis market report based on product & service, application, and region:

Product & Service Outlook (Revenue, USD Million, 2018 - 2030)

• Oligonucleotides

o DNA

o Column-based

o Array-based

o RNA

o By Technology

o Column-based

o Array-based

o By Type

o Short RNA Oligos (<65 nt)

o Long RNA Oligos (>65 nt)

o CRISPR (sgRNA)

• Equipment/Synthesizer

• Reagents

• Services

o DNA

o Custom Oligo Synthesis Services

o 25 nmol

o 50 nmol

o 200 nmol

o 1000 nmol

o 10000 nmol

o Modification Services

o Purification Services

o RNA

o Custom Oligo Synthesis Services

o 25 nmol

o 100 nmol

o 1000 nmol

o 10000 nmol

o Modification Services

o Purification Services

Application Outlook (Revenue, USD Million, 2018 - 2030)

• PCR Primers

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• PCR Assays & Panels

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Sequencing

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• DNA Microarrays

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Fluorescence In Situ Hybridization (FISH)

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Antisense Oligonucleotides

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Other Applications

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o U.K.

o France

o Spain

o Italy

o Denmark

o Sweden

o Norway

• Asia Pacific

o China

o Japan

o India

o South Korea

o Australia

o Thailand

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa (MEA)

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global optical genome mapping market size was valued at USD 104.1 million in 2023 and is expected to grow at a CAGR of 26.76% from 2024 to 2030. 

• The global therapeutic drug monitoring market size was valued USD 1.80 billion in 2023 and is projected to grow at a CAGR of 3.8% from 2024 to 2030. 

Key Companies & Market Share Insights

Some of the key players operating in the market include Merck KGaA, Thermo Fisher Scientific, Inc., and Agilent Technologies. These players focus on business strategies such as partnerships/collaborations, product launches, and expansion. Twist Bioscience, Biolegio, and LGC Biosearch Technologies are some of the emerging market participants in the oligonucleotide market. These players primarily focus on expansion and partnerships to strengthen their position in the market.

Key Oligonucleotide Synthesis Companies:

• Thermo Fisher Scientific, Inc.

• Merck KGaA

• Danaher Corporation

• Dharmacon Inc.

• Agilent Technologies

• Bio-synthesis

• Kaneka Eurogentec S.A

• LGC Biosearch Technologies

• Biolegio

• Twist Bioscience

Recent Developments

• In October 2023, IDT inaugurated a new therapeutic manufacturing facility to meet the increasing demand in genomic medicine. The new facility is equipped to support the production of therapeutic oligonucleotides, catering to the expanding needs in the field of genomics and personalized medicine.

• In September 2023, Danaher Corporation (Integrated DNA Technologies) introduced a range of xGen NGS products tailored for the Ultima Genomics UG 100TM platform. The suite includes adapters, primers, and universal blockers, catering to various applications such as DNA, RNA, & methylation sequencing workflows. This offering is complemented by IDT's proven hybridization capture chemistry, enhancing versatility for researchers.

• In July 2023, Analytix introduced two new instruments designed for organic synthesis, including wavePREP, tailored for oligonucleotide synthesis, and Xelsius, a workstation for multireaction synthesis.

• In May 2023, GenScript expanded its life sciences facility in Zhenjiang, Jiangsu, China, to offer a rapid, high-purity oligonucleotide and peptide synthesis service tailored for research & development as well as preclinical applications.

• In May 2023, Twist Bioscience and CeGaT GmbH launched the Twist Alliance CeGaT RNA Fusion Panel. This collaborative effort aims to provide a specialized tool for oncology research, facilitating the detection of RNA fusions and enabling transcript variant analysis. RNA fusions, a result of chromosomal arrangements often seen in cancers, can now be efficiently studied using this newly introduced panel.

• In February 2023, Fluor Corp. and Agilent Technologies, Inc. collaborated to enhance its oligonucleotide therapeutics manufacturing facility in Frederick, Colorado. Under this collaboration, Fluor is expected to support the project's engineering and procurement. The total value of the project is evaluated at USD 725 million.

Order a free sample PDF of the Oligonucleotide Synthesis Market Intelligence Study, published by Grand View Research.

[tamanna31]

Biobanks Market 2024 Analysis, Research, Review, Applications and Forecast to 2030

Biobanks Industry Overview

The global biobank market size was estimated at USD 76.74 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2030.

High investments in the R&D of advanced therapies, such as regenerative medicine, personalized medicine, and cancer genomic studies, are some of the driving factors. Moreover, the onset of COVID-19 has put biobanks at the forefront of the pandemic control measures, resulting in the organic revenue growth of the market. The COVID-19 outbreak had a major influence on the biobanking industry. Biobanking is important for the diagnosis & production of medicines for a variety of disorders. International initiatives to produce vaccines and other medicines to prevent the spread of the virus have been urgently needed.

The collection, processing, and analysis of patient samples are at the frontline of the COVID-19 crisis. For example, the Health Minister announced EUR 2 million in financing for the National Irish COVID-19 Biobank (NICB) in a July 2021 update from the Government of Ireland. The NICB has become a critical part of Ireland’s COVID-19 pandemic response. According to a February 2021 release, the Sample Collection Database was designed by the SciLifeLab Data Centre in partnership with Biobank Sweden and the research area ‘Biobanks for COVID-19’ of the SciLifeLab & KAW National COVID-19 research program.

Gather more insights about the market drivers, restrains and growth of the Biobanks Market

Furthermore, Tulane University announced a new COVID-19 biobank containing blood & cell samples from survivors in July 2021 to aid researchers in determining why some people heal rapidly while others have long-term effects. As a result, such activities show that the outbreak of the pandemic boosted the demand for biobank services, benefiting the global economy.

The increasing popularity of precision/personalized medicine and genetic testing has been a key driver of the market. Biobanks have been playing a significant role in biomedical research. Over the past few decades, there have been several advances in platforms and tools used in genetic studies. This has led to an increase in demand for biospecimens from clinical labs to develop assays for genetic testing. Collaborations between private and public institutions in biobanking have played a crucial role in market progression.

Digitalization, precision medicine, and virtualization are rapidly changing the biobanking industry through the development of novel methods and concepts of synergies initiated by public and private organizations. Companies across all fields are partnering with biobanks, which accelerates the market revenue. For instance, in October 2023, UK Biobank partnered with several philanthropists. Through this partnership, UK Biobank will access USD 34.5 million in funding.

An exponential increase in the number of global cases has rendered the significance of biobanks in containing the spread of the virus. High-quality COVID-19 specimens are required and helpful for both research and diagnostic purposes, and biobanks are considered vital repositories for these samples. Thus, biobanks are gaining ground to support clinical research and drug discovery processes to combat this global disaster.

Developing countries from the Middle East region are investing in biobanks to advance the medical research domain in the country. For instance, in September 2023, the Crown Prince of Abu Dhabi announced the launch of a biobank to support the requirement of personalized medicine through advanced treatments that utilize human tissues and stem cells in medical research. This research will help treat over 80 diseases and immune system issues. Moreover, it strengthens the position of the UAE in the global biobanks market.

Browse through Grand View Research's Biotechnology Industry Research Reports.

The global plasmid purification market size was estimated at USD 1.72 billion in 2023 and is projected to grow at a CAGR of 11.60% from 2024 to 2030. 

The global enzymatic DNA synthesis market size was estimated at USD 232.4 million in 2023 and is projected to grow at a CAGR of 26.4% from 2024 to 2030.

Key Companies & Market Share Insights

Some of the key players operating in the market are adopting various organic & inorganic strategies such as collaborations with biobanking service providers and technological innovation to advance their product offerings in the biobanking industry. 

Key Biobanks Companies:

Thermo Fisher Scientific Inc.

Merck KGaA

Qiagen

Hamilton Company

Tecan Trading AG

Danaher Corporation

Becton, Dickinson, and Company (BD)

Biocision, LLC.

Taylor-Wharton

Charles River Laboratories

Lonza

Stemcell Technologies

Biovault Family

Promocell Gmbh

Precision Cellular Storage Ltd. (Virgin Health Bank)

Recent Developments

In October 2023, AstraZeneca research announced unique relationships between rare changes in plasma proteins and genes that could enhance drug discovery with data from more than 50,000 UK Biobank participants.

Similarly, in January 2023, Hamad Medical Corporation, in collaboration with Qatar BioBank, launched a Tissue Biobank Service in Qatar. This biobank will focus on collecting samples and finding new potential treatments for heart diseases & cancer.

In January 2023, Quibim and European Commission launched European Commission’s European Federation for Cancer Images (EUCAIM) biobank. This biobank will focus on developing treatments for cancers along with early detection techniques.

In December 2023, Charles River Laboratories International, Inc. announced an agreement with CELLphenomics to expand 3D In Vitro Services for drug screening of cancer therapy. CELLphenomics biobank has over 500 in vitro models from around 20 tumor entities. It offers one of the largest complex in vitro models of rare and ultra-rare tumors like thymomas or sarcomas.

. In July 2023, Tecan announced the launch of Phase Separator. It has several applications in biobanking and liquid biopsy and is expected to benefit proteomics, genomics and across numerous disease areas, from neurodegenerative and oncology diseases to metabolic disorders.

In January 2023, Thermo Fisher Scientific, Inc. announced its participation as a founding sponsor of Momentum Labs, a new biotech hub located in Alachua, Florida. This collaboration aims to support the growth of innovative biotech startups and drive advancements in the industry. With Thermo Fisher's expertise in the life sciences and its commitment to innovation, the company is well-positioned to play a significant role in the success of Momentum Labs and the companies it supports. The establishment of this hub is expected to have a positive impact on the local economy and further solidify Florida's position as a hub for biotech innovation.

In February 2022, Hamilton company expanded its range of VersoQ series of storage systems at a debut at SLAS 2022 conference. This would increase the company’s product offerings in biobanking.

Order a free sample PDF of the Biobanks Market Study, published by Grand View Research.

[mitinosh]

Stem Cell Assay Market Players, Share, Growth, Latest Trends, Global Forecast 2030

[global-research-report]

Global Induced Pluripotent Stem Cells Market: Opportunities in Drug Development and Disease Treatment

The global induced pluripotent stem cells market size is expected to reach USD 3.31 billion by 2030, registering to grow at a CAGR of 10.21% from 2024 to 2030 according to a new report by Grand View Research, Inc. The market for induced pluripotent stem cells (iPSC) is expanding quickly. The ability of induced pluripotent stem cells to generate any cell or tissue essential by the body to fight or combat illnesses such as leukemia, spinal cord injury, cardiovascular disease, and diabetes is the primary reason for their utilization.

Other factors driving market expansion include higher research funding, an increase in the number of genomics initiatives, and a surge in the application of genome engineering in personalized drugs. This has accelerated the adoption of iPSC, resulting in the market's profitable revenue growth. For instance, in October 2020, Axxam S.p.A. & FUJIFILM Cellular Dynamics, Inc. announced a strategic partnership to advance the drug discovery process. Through the use of the most cutting-edge drug discovery techniques to enable target evaluation, High-Throughput Screening (HTS), & High-Content Screening, the partnership will give drug development researchers along with scientists access to an integrative platform of hiPSC-based assays.

Investments in healthcare development and research have expanded significantly in recent years, and this trend is projected to have a significant impact on induced pluripotent stem cell demand over the forecast period. The expanding spectrum of human iPSC cell lines' applications in precision medicine and the growing emphasis on stem cell therapeutic applications are predicted to be important factors driving induced pluripotent stem cell market expansion. For instance, in March 2021, Sana Biotechnology, Inc. received authorization to use FUJIFILM Cellular Dynamics' iPSC platform for the creation of commercially available cell therapies, according to a joint statement from both companies. Cell therapies can improve, fix, or substitute human biology, including cells, tissues, and organs.

The rise in research activity during the COVID-19 pandemic also enhanced iPSC-based research. In addition, scientists' ongoing efforts to discover novel therapies and treatments to manage the SARS CoV-2 infection have increased the need for iPSCs as research tools. Furthermore, induced pluripotent stem cells can create organoids or organ models that are physiologically equivalent, thus they can be utilized to study the pathophysiology of viral infection in humans. Thus, propelling the industry growth.

Furthermore, the government and commercial sectors are expanding funding along with growing industry that focuses on various scientific activities linked to iPSCs, and people are becoming more aware of stem cells through various organizations. However, challenges such as the high cost of cell reprograming, ethical concerns, and lengthy processes are inhibiting the growth of the induced pluripotent stem cell industry to a certain extend Moreover, low efficiency, potential tumor risk, and insufficient programming are other concerns restricting the expansion of the iPSC market.

Induced Pluripotent Stem Cells Market Report Highlights

By derived cell type, the fibroblasts segment accounted for the largest share of 30.51% in 2023. The growing preference among healthcare professionals for fibroblast as potential treatments for skin problems are propelling the segment growth.

By application, the drug developmentsegment accounted for the largest share of 49.03% in 2023. The prevalence of chronic diseases, sedentary lifestyle, and others increase the demand for personalized therapies, and the increasing interest of pharma & biotech companies to develop drugs with the help of iPS cells promotes the industry growth.

By end-user, the pharmaceutical & biotechnology companies segment accounted for the largest share of 59.83% in 2023. This segment is projected to dominate the market since they make and develop various stem cell products & technology for various diseases employing induced pluripotent stem cells.

North America held the larger share of 36.11% in 2023. This is mostly due to increased use of innovative systems and technologies in drug research, toxicity testing, and disease modeling, as well as the region's growing acceptance of stem cell therapies are the major reasons for driving the market.

Induced Pluripotent Stem Cells Market Segmentation

Grand View Research has segmented the global induced pluripotent stem cells market based on derived cell type, application, end-use, and region:

Induced Pluripotent Stem Cells Derived Cell Type Outlook (Revenue, USD Million, 2018 - 2030)

Hepatocytes

Fibroblasts

Keratinocytes

Amniotic Cells

Others

Induced Pluripotent Stem Cells Application Outlook (Revenue, USD Million, 2018 - 2030)

Drug Development     

Tissue Engineering & Regenerative Medicine

Neurology

Orthopedics

Oncology

Cardiovascular and Myocardial Infraction

Diabetes

Others

Toxicology Research  

Disease Modeling

Induced Pluripotent Stem Cells End-use Outlook (Revenue, USD Million, 2018 - 2030)

Academic & Research Institutes

Pharmaceutical & Biotechnology Companies

Others

Induced Pluripotent Stem Cells Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

South Korea

Australia

Thailand

Latin America

Brazil

Argentina

MEA

South Africa

Saudi Arabia

UAE

Kuwait

Order a free sample PDF of the Induced Pluripotent Stem Cells Market Intelligence Study, published by Grand View Research.

[datahorizzon-research1]

Technological Advances Shaping Flow Cytometry: A 2024-2032 Forecast

In 2022, the flow cytometry market reached a value of USD 4.5 Billion and is poised to hit USD 9.6 Billion by 2032, showing a robust CAGR of 7.9%.

Widely employed in cell biology, immunology, oncology research, and clinical diagnostics, flow cytometry stands as a formidable technique. By passing cells through a beam of light while in fluid suspension, researchers and clinicians delve into their physical and chemical traits. This method illuminates crucial cellular properties like size, complexity, surface markers, and intracellular molecules, offering invaluable insights.

Request Sample Report: https://datahorizzonresearch.com/request-sample-pdf/flow-cytometry-market-2689

Here’s an overview of the flow cytometry market:

Market Size and Growth: The flow cytometry market has been experiencing steady growth, driven by advancements in technology, increasing applications in research and clinical settings, and rising demand for personalized medicine.

Technology Trends: Recent technological advancements in flow cytometry include the development of high-parameter flow cytometers capable of analyzing multiple parameters simultaneously, such as spectral flow cytometry and mass cytometry (cytometry by time-of-flight, CyTOF).

Applications: Flow cytometry finds applications in various fields, including immunology (e.g., immunophenotyping, cell proliferation assays), cancer research (e.g., minimal residual disease detection, drug screening), stem cell research, microbiology, and infectious disease diagnostics.

Market Players: The flow cytometry market is highly competitive and includes major players such as BD Biosciences (a division of Becton, Dickinson and Company), Beckman Coulter (a subsidiary of Danaher Corporation), Thermo Fisher Scientific, Sysmex Corporation, and Miltenyi Biotec, among others.

Emerging Markets: Emerging markets, particularly in Asia-Pacific and Latin America, present significant growth opportunities for flow cytometry companies due to increasing research activities, growing healthcare expenditure, and rising awareness about advanced diagnostic technologies.

For Further Information Regarding this Report: Ask For Discount:

https://datahorizzonresearch.com/ask-for-discount/flow-cytometry-market-2689

Top Companies are:

· Danaher Corp.

· Becton, Dickinson, and Company (BD)

· Sysmex Corp.

· Agilent Technologies, Inc.

· Apogee Flow Systems Ltd.

· Bio-Rad Laboratories, Inc.

· Thermo Fisher Scientific, Inc.

· Stratedigm, Inc.

· DiaSorin SpA

· Miltenyi Biotec

· Sony Biotechnology

Market Segmentations:

By Product (2023–2032)

Instruments

Reagents & Consumables

Software

Accessories

Services

By Technology (2023–2032)

Cell-based

Bead-based

By Application (2023–2032)

Research

Industrial

Clinical

By End-use (2023–2032)

Commercial Organizations

Hospitals

Academic Institutes

Clinical Testing Labs

Regional Analysis:

Geographically, the flow cytometry market has been divided into North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America is expected to hold a substantial market share in the coming years, driven by ongoing technological advancements and a vibrant research and development ecosystem. The United States leads in this market owing to its robust healthcare industry, extensive research endeavors, and a notable prevalence of chronic ailments. Moreover, the increasing focus on precision medicine and tailored therapies contributes significantly to the market’s expansion.

Key highlights of the report include:

1. The report delivers thorough Market analysis, furnishing valuable insights to guide strategic decision-making.

2. The comprehensive research outlined in the study enhances the depth of your presentations and marketing strategies.

3. By offering crucial insights into key market competitors, the study empowers businesses with a strategic edge.

4. It delivers a precise assessment of evolving market dynamics, ensuring readers stay abreast of the latest industry trends.

5. With meticulous breakdowns of various market niches, the report facilitates informed decision-making processes.

Check Out More Related Reports:

Smart Fleet Management Market

Vehicle Roadside Assistance Market

[blog-site-for-market-research]

Global High Throughput Screening Market Size| Growth | Scope, 2032

Market Overview

The global high throughput screening market is expected to mature at a 7.5% CAGR during the forecast period.

Market Highlights

High throughput screening has achieved mainstream acceptance over the past two decades and has become a traditional drug discovery tool in the pharmaceutical industry. Factors such as technical developments in HTS and rising pharmaceutical R&D spending are driving the global high throughput screening industry. In addition, demand development is projected to be powered by the growing research activities in stem cells & toxicology and emerging markets. In recent years, technological developments such as liquid handling automation, the development of novel technology systems, and computational methods to deal with vast volumes of data have increasingly powered the global demand for high-performance screening instruments. Rising rivalry for pioneering drug development and marketing demand for high-performance screening instruments among pharmaceutical firms is growing at a rapid rate.

Strong capital spending, on the other hand, is expected to hamper demand growth during the projected period. In addition, the high time consumption and high cost of high-throughput screening techniques can impede the growth of the market.

Segmental Analysis

Based on product & service, technology, applications, end user, and region, the global high throughput screening market has been segmented.

The global market has been bifurcated into reagents & assay kits, instruments, consumables & accessories, software and services, based on product & service.

Due to the large number of reagents and assay kits used in HTS techniques and increased government funding for life science research, the reagents & assay kits segment is expected to hold a significant share in the market.

Segmental Analysis

The worldwide market is divided into cell-based assays, 2D cell culture, 3D cell culture, 3D cell culture, perfusion cell culture, laboratory-on-a-chip (LOC), ultra-high-throughput screening, bioinformatics, and label-free technology based on technology.

Based on use, the global market is segmented into target recognition & confirmation, primary and secondary screening, toxicology assessment, and others. Due to rising pharmaceutical R&D and the increasing prevalence of many diseases, the application category is projected to be the fastest-growing.

The global market is categorised into pharmaceutical and biotechnology firms, university and government agencies, contract research organisations, and others, depending on end users.

Regional Overview

North America and Latin America have been segmented into the high-performance scanning industry in the Americas, with the North American market split into the US and Canada.

Due to the rising per capita healthcare spending and the fast penetration of advanced technologies in the region, the demand in the Americas is projected to dominate the global high throughput screening market. It is expected that the will adoption of HTS in the US and Canada will fuel the growth of the sector. In addition, growing spending on research by healthcare institutions is expected to boost demand growth in this field.

In Europe, the market was projected to see a substantial amount of growth. The existence of a well-established healthcare sector and the participation of main corporations can be attributed to this.

Leading to a rise in chronic diseases and rising government measures for health care reforms, the Asia-Pacific market is expected to have a steady growth rate during the forecast period.

The Middle East & Africa market is estimated to account for the lowest share of the global market because of the region's low per capita disposable income.

Competitive Dashboard

The key players operating in the global high throughput screening market research are Aurora Biomed Inc. (Canada), Danaher (US), PerkinElmer (US), Tecan (Switzerland), Hamilton (US), Axxam (Italy), Merck Group (Germany), Corning (US), BioTek (US), Beckman Coulter, Inc. (US), Agilent Technologies Inc. (US), Luminex Corporation (US), and Roche (Switzerland).

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: https://www.marketresearchfuture.com